Delivery Order SPE2DB25D9320-SPE2DB25FWFCF
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 80 mg tablets (60-count units). The contract, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. The awardee, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order from its location in the same city....
- The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 80 mg tablets (60-count units). The contract, which became effective on July 23, 2025, with an ultimate completion date of July 24, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its...
- The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for 60 tablets of Xtandi 80 mg, a prescription oncology medication. This firm fixed-price delivery order was awarded on July 21, 2025, with an ultimate completion date of July 22, 2025, and carries no set-aside designation. The order will be fulfilled and delivered to Park Ridge, Illinois, where DMS Pharmaceutical Group maintains its operations as a woman-owned small business pharmaceutical...
- The U.S. Defense Logistics Agency (DLA) awarded a $4,169.59 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order is for the supply of 4,566,561,052 units of the prescription drug Xtandi 40 mg tablet, with a completion date of November 27, 2024. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA...
- This is a $4,169.59 firm fixed-price delivery order awarded by the Defense Logistics Agency's Medical Supply Chain group to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The order is for 120 tablets of the prescription drug Xtandi 40mg, with an ultimate completion date of March 20, 2024. DMS Pharmaceutical Group holds a broader indefinite delivery contract (SPE2DB) with the Defense Logistics Agency valued at up to $4,999,999 through 2025, which...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 80 mg tablets (60-count units) under contract number 4569035597. The award, valued at $4,169.59 with a firm fixed-price structure, was executed on August 8, 2025, with an ultimate completion date of August 11, 2025. This delivery order carries no set-aside designation and represents a continuation of...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for 60 tablets of Xtandi 80 mg, an oncology medication used to treat prostate cancer. The award, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, carries no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected to fulfill this order under its...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $8,339.18 by the Defense Logistics Agency on July 28, 2025, for the supply of Xtandi 80 mg tablets (60-count packages). This firm fixed-price delivery order, with an ultimate completion date of July 29, 2025, represents a specific product requisition under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The...
- The Defense Logistics Agency awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 40 mg capsules (120-unit quantity). The contract, issued on August 8, 2025, with an ultimate completion date of August 11, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at $499,999,999 through November 2026, which enables...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,934.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The contract, effective August 12, 2025 with completion by August 13, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This award represents a single transaction under DMS Pharmaceutical Group's larger...
- SPE2DB25D9320Indefinite Delivery Contract
- SPE2DB25D9320-SPE2DB25FWFCFDelivery Order
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for 60 tablets of Xtandi 80 mg, a prescription oncology medication. The contract was awarded on August 13, 2025, with an ultimate completion date of August 14, 2025, and will be performed at the vendor's location in Park Ridge, Illinois. This delivery order carries no set-aside designation and represents a discrete pharmaceutical supply requirement within DLA's broader medical logistics operations. This award is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA valued at $499,999,999 through November 2026, which authorizes the issuance of firm fixed-price delivery orders for pharmaceutical products supporting Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group is a woman-owned small business pharmaceutical wholesaler that has established itself as a significant supplier within the federal pharmaceutical supply chain. The company's extensive contract portfolio with DLA demonstrates its capability to supply a comprehensive range of branded and generic prescription drugs, biologics, and medical consumables to military health systems nationwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.2k | 8/13/25 |